Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AlphaRx Establishes R&D Facility In Shanghai
AlphaRx has selected locations in Hong Kong and Shanghai for its corporate headquarters and a new R&D facility respectively. The company said that the initiative will spearhead a
AlphaRx has selected locations in Hong Kong and Shanghai for its corporate headquarters and a new R&D facility respectively. The company said that the initiative will spearhead a
Shire has recalled five lots and voluntary market withdrawal of one lot of the attention-deficit/hyperactivity disorder (ADHD) patch Daytrana. Shire is taking this action because some Daytrana patches
Pfizer is entering into a three-year, $9m research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General
A new plastic film, for which a patent has been applied, will protect Basf’s pharmaceutical excipient polyvinylpyrrolidone (PVP) in future even better against the penetration of atmospheric oxygen
The Natural Step and The Dow Chemical has entered into an agreement that is expected to help both organisations to advance their sustainability missions and goals. The agreement,
Noxxon Pharma, developing medicines based on its proprietary Spiegelmer technology, has achieved an important milestone in its drug discovery and development partnership with Eli Lilly and Company. Noxxon’s
Procter & Gamble Oral Care has unveiled the new Crest Pro-Health system, a 3-step oral hygiene regimen, through which consumers can be virtually plaque free. Robert Gerlach, member
Oliver-Tolas Healthcare Packaging has appointed Jane Severin, as director of technology. Dr Severin is an IoPP Certified Packaging Professional with a BS and a PhD in Packaging from
Sanofi-aventis has entered into an exclusive global licensing agreement with the Rockefeller University, New York, for a monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal
Alkermes and Acceleron Pharma have enetred into a license agreement. Under the terms of the agreement, Alkermes will have worldwide rights to the Medifusion technology in return with